Browsing Tag
Dynavax Technologies
3 posts
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
December 29, 2025
Dynavax (NASDAQ: DVAX) targets 60% U.S. hepatitis B market share by 2030 amid COVID vaccine deal, $100m buyback
Dynavax targets 60% of U.S. hepatitis B vaccine market by 2030, expands COVID-19 pipeline, and authorizes $100M buyback. Read what this signals for investors.
November 6, 2025
Dynavax begins clinical trial for new shingles vaccine candidate, Z-1018
Dynavax Technologies Corporation, a renowned player in the biopharmaceutical sector, has made headlines with the initiation of a…
June 28, 2024